Mark Peyrot

Mark Peyrot

Mark Peyrot received his Ph.D. in sociology from UCLA and served a postdoctoral fellowship in behavioral science at the University of Kentucky Medical Center. He was the founding director of the Loyola University Maryland Center for Social and Community Research. He now is professor of sociology at Loyola University Maryland and serves on the research faculty in the School of Medicine at Johns Hopkins University.

Dr. Peyrot’s current research examines psychosocial aspects in the management of and adjustment to chronic disease, especially diabetes. His 200+ publications include several edited collections as well book chapters and articles in scientific journals. He has received grants from the National Science Foundation, the American Association of Diabetes Educators, The American Cancer Society, the American Diabetes Association, the American Lung

Association, among others.

Dr. Peyrot has served leadership positions in several professional organizations, including the Society for the Study of Social Problems, the American Sociological Association, the American Diabetes Association, and the American Association of Diabetes Educators. He has served on several NIH review panels and as an editorial board member for numerous sociology and medical journals. In addition to serving as an advisor to pharmaceutical and health care organizations, Dr. Peyrot is an internationally recognized speaker for audiences of health care administrators, diabetes care providers and educators, and persons with diabetes and their

families.

The Johns Hopkins University, School of Medicine

102 Publications

This is a list of publications by this researcher, listed chronologically starting with the most recent first. New publications appear in this list weekly. The source of publications for this application is PubMed, so only PubMed publications are included.

? 1.

Richard R Rubin; Mark Peyrot;

Health-related quality of life and treatment satisfaction in the

Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial.

Diabetes technology & therapeutics 2012;14(2):143-51.

? 2.

Mark Peyrot; Richard R Rubin

Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled technosphere insulin and basal insulin versus premixed insulin.

Diabetes technology & therapeutics 2011;13(12):1201-6.

? 3.

Richard R Rubin; Mark Peyrot; Catherine P Metzinger; Yaping Xu;

Barbara Lippe; Leah McCormack; Daniel Aaron Davis

An observational study to validate the Satisfaction Measure of the

Injection of Growth Hormone Therapy (SMIGHTy) questionnaire.

Current medical research and opinion 2011;27(10):2009-17.

? 4.

Felicia Hill-Briggs; Mariana Lazo; Mark Peyrot; Angela Doswell; Yi-Ting

Chang; Martha N Hill; David Levine; Nae-Yuh Wang; Frederick L Brancati Effect of problem-solving-based diabetes self-management training on

diabetes control in a low income patient sample.

Journal of general internal medicine 2011;26(9):972-8.

? 5.

Barbara Stetson; David Schlundt; Mark Peyrot; Paul Ciechanowski; Mary M Austin; Deborah Young-Hyman; June McKoy; Micki Hall; Rashida

Dorsey; Karen Fitzner; et al.

Monitoring in diabetes self-management: issues and recommendations for improvement.

Population health management 2011;14(4):189-97.

? 6.

Mark Peyrot; Richard R Rubin; Xiaojing Chen; Juan P Frias

Associations between improved glucose control and patient-reported outcomes after initiation of insulin pump therapy in patients with type 2 diabetes mellitus.

Diabetes technology & therapeutics 2011;13(4):471-6.

?7.

Arie Nouwen; Giesje Nefs; Isabela Caramlau; Martin Connock; Kirsty Winkley; Cathy E Lloyd; Mark Peyrot; Fran?ois Pouwer;

Prevalence of depression in individuals with impaired glucose

metabolism or undiagnosed diabetes: a systematic review and

meta-analysis of the European Depression in Diabetes (EDID) Research Consortium.

Diabetes care 2011;34(3):752-62.

?8.

R R Rubin; M Peyrot

Factors associated with physician perceptions of and willingness to

recommend inhaled insulin.

Current medical research and opinion 2011;27(2):285-94.

?9.

Jennie H Best; Richard R Rubin; Mark Peyrot; Yan Li; Ping Yan; Jaret Malloy; Louis P Garrison

Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.

Diabetes care 2011;34(2):314-9.

?10.

Mark Peyrot; Richard R Rubin

Factors associated with persistence and resumption of insulin pen use for patients with type 2 diabetes.

Diabetes technology & therapeutics 2011;13(1):43-8.

?11.

Martha M Funnell; Tammy L Brown; Belinda P Childs; Linda B Haas;

Gwen M Hosey; Brian Jensen; Melinda Maryniuk; Mark Peyrot; John D Piette; Diane Reader; et al.

National Standards for diabetes self-management education.

Diabetes care 2011;34 Suppl 1():S89-96.

?12.

Mark Peyrot; Richard R Rubin

Perceived medication benefits and their association with interest in using inhaled insulin in type 2 diabetes: a model of patients' cognitive

framework.

Patient preference and adherence 2011;5():255-65.

?13.

A Nouwen; K Winkley; J Twisk; C E Lloyd; M Peyrot; K Ismail; F Pouwer;

Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis.

Diabetologia 2010;53(12):2480-6.

?14.

Richard R Rubin; Yong Ma; Mark Peyrot; David G Marrero; David W Price;

Elizabeth Barrett-Connor; William C Knowler;

Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program

outcomes study.

Diabetes care 2010;33(12):2549-51.

?15.

Richard R Rubin; Mark Peyrot; Xiaojing Chen; Juan P Frias

Patient-reported outcomes from a 16-week open-label, multicenter

study of insulin pump therapy in patients with type 2 diabetes mellitus.

Diabetes technology & therapeutics 2010;12(11):901-6.

?16.

J S Gonzalez; L Vileikyte; J S Ulbrecht; R R Rubin; A P Garrow; C Delgado;

P R Cavanagh; A J M Boulton; M Peyrot

Depression predicts first but not recurrent diabetic foot ulcers.

Diabetologia 2010;53(10):2241-8.

?17.

Richard R Rubin; Mark Peyrot

Patient-reported outcomes and diabetes technology: a systematic

review of the literature.

Pediatric endocrinology reviews : PER 2010;7 Suppl 3():405-12.

?18.

R R Rubin; S A Gaussoin; M Peyrot; V DiLillo; K Miller; T A Wadden; D S West; R R Wing; W C Knowler;

Cardiovascular disease risk factors, depression symptoms and

antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes.

Diabetologia 2010;53(8):1581-9.

Mark Peyrot; Richard R Rubin; William H Polonsky; Jennie H Best

Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs.

Current medical research and opinion 2010;26(5):1047-54.

?20.

Mark Peyrot; Richard R Rubin; Kamlesh Khunti

Addressing barriers to initiation of insulin in patients with type 2

diabetes.

Primary care diabetes 2010;4 Suppl 1():S11-8.

?21.

Mark Peyrot; Richard R Rubin; Davida F Kruger; Luther B Travis

Correlates of insulin injection omission.

Diabetes care 2010;33(2):240-5.

?22.

Martha M Funnell; Tammy L Brown; Belinda P Childs; Linda B Haas;

Gwen M Hosey; Brian Jensen; Melinda Maryniuk; Mark Peyrot; John D Piette; Diane Reader; et al.

National standards for diabetes self-management education.

Diabetes care 2010;33 Suppl 1():S89-96.

?23.

Mark Peyrot; Richard R Rubin

Effect of technosphere inhaled insulin on quality of life and treatment satisfaction.

Diabetes technology & therapeutics 2010;12(1):49-55.

Richard R Rubin; Mark Peyrot

Psychometric properties of an instrument for assessing the experience of patients treated with inhaled insulin: the inhaled insulin treatment questionnaire (IITQ).

Health and quality of life outcomes 2010;8():32.

?25.

Kelley Newlin; Gail D Melkus; Mark Peyrot; Harold G Koenig; Emily Allard;

Deborah Chyun

Coping as a mediator in the relationships of spiritual well-being to

mental health in black women with type 2 diabetes.

International journal of psychiatry in medicine 2010;40(4):439-59.

?26.

Henk-Jan Aanstoot; Barbara Anderson; Thomas Danne; Larry Deeb;

Alexandra Greene; Francine Kaufman; Karin Lange; Anja ?stergren

Nielsen; Mark Peyrot; et al.

Outcomes of the DAWN Youth Summits of 2007 and 2008.

Pediatric diabetes 2009;10 Suppl 13():21-7.

?27.

Mark Peyrot;

The DAWN Youth WebTalk Study: methods, findings, and implications.

Pediatric diabetes 2009;10 Suppl 13():37-45.

?28.

Henk-Jan Aanstoot; Barbara Anderson; Thomas Danne; Larry Deeb;

Alexandra Greene; Francine Kaufman; Karin Lange; Anja ?stergren

Nielsen; Mark Peyrot; et al.

Changing the future of diabetes.

Pediatric diabetes 2009;10 Suppl 13():58-60.

?29.

Richard R Rubin; Mark Peyrot; Davida F Kruger; Luther B Travis

Barriers to insulin injection therapy: patient and health care provider perspectives.

The Diabetes educator 2009;35(6):1014-22.

?30.

Richard R Rubin; Mark Peyrot

Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump.

Journal of diabetes science and technology 2009;3(6):1402-10.

?31.

Mark Peyrot; Richard R Rubin

How does treatment satisfaction work?: Modeling determinants of

treatment satisfaction and preference.

Diabetes care 2009;32(8):1411-7.

?32.

Mark Peyrot; Soren E Skovlund; Ruediger Landgraf

Epidemiology and correlates of weight worry in the multinational

Diabetes Attitudes, Wishes and Needs study.

Current medical research and opinion 2009;25(8):1985-93.

?33.

J H Best; K S Boye; R R Rubin; D Cao; T H Kim; M Peyrot

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily.

Diabetic medicine : a journal of the British Diabetic

Association 2009;26(7):722-8.

?34.

L Vileikyte; M Peyrot; J S Gonzalez; R R Rubin; A P Garrow; D Stickings;

C Waterman; J S Ulbrecht; P R Cavanagh; A J M Boulton

Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study.

Diabetologia 2009;52(7):1265-73.

?35.

Loretta Vileikyte; Richard R Rubin; Mark Peyrot; Jeffrey S Gonzalez;

Andrew J M Boulton; Jan S Ulbrecht; Peter R Cavanagh

Diabetic feet.

The British journal of general practice : the journal of the Royal College of General Practitioners 2009;59(561):290.

?36.

Mark Peyrot; Richard R Rubin; Martha M Funnell; Linda M Siminerio Access to diabetes self-management education: results of national

surveys of patients, educators, and physicians.

The Diabetes educator 2009;35(2):246-8, 252-6, 258-63.

?37.

Richard R Rubin; Mark Peyrot

Psychometric properties of an instrument for assessing treatment

satisfaction associated with pramlintide use.

The Diabetes educator 2009;35(1):136-46.

?38.

Martha M Funnell; Tammy L Brown; Belinda P Childs; Linda B Haas;

Gwen M Hosey; Brian Jensen; Melinda Maryniuk; Mark Peyrot; John D Piette; Diane Reader; et al.

National standards for diabetes self-management education.

Diabetes care 2009;32 Suppl 1():S87-94.

?39.

Mark Peyrot; Richard R Rubin

Patient-reported outcomes for an integrated real-time continuous

glucose monitoring/insulin pump system.

Diabetes technology & therapeutics 2009;11(1):57-62.

?40.

Jeffrey S Gonzalez; Mark Peyrot; Lauren A McCarl; Erin Marie Collins;

Luis Serpa; Matthew J Mimiaga; Steven A Safren

Depression and diabetes treatment nonadherence: a meta-analysis.

Diabetes care 2008;31(12):2398-403.

?41.

Mark Peyrot; Richard R Rubin; William H Polonsky

Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy.

Diabetes technology & therapeutics 2008;10(6):461-6.

?42.

Felicia Hill-Briggs; Ronda Renosky; Mariana Lazo; Lee Bone; Martha Hill;

David Levine; Frederick L Brancati; Mark Peyrot

Development and pilot evaluation of literacy-adapted diabetes and CVD education in urban, diabetic African Americans.

Journal of general internal medicine 2008;23(9):1491-4.

?43.

Mark Peyrot; Richard R Rubin

Physician perception and recommendation of insulin pens for patients with type 2 diabetes mellitus.

Current medical research and opinion 2008;24(8):2413-22.

?44.

Richard R Rubin; Mark Peyrot

Factors affecting use of insulin pens by patients with type 2 diabetes.

Diabetes care 2008;31(3):430-2.

?45.

Richard R Rubin; Yong Ma; David G Marrero; Mark Peyrot; Elizabeth L Barrett-Connor; Steven E Kahn; Steven M Haffner; David W Price;

William C Knowler;

Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program.

Diabetes care 2008;31(3):420-6.

?46.

Martha M Funnell; Tammy L Brown; Belinda P Childs; Linda B Haas;

Gwen M Hosey; Brian Jensen; Melinda Maryniuk; Mark Peyrot; John D Piette; Diane Reader; et al.

National standards for diabetes self-management education.

Diabetes care 2008;31 Suppl 1():S97-104.

?47.

Mark Peyrot; Richard R Rubin

Access to diabetes self-management education.

The Diabetes educator 2008;34(1):90-7.

?48.

Mark Peyrot; Richard R Rubin

Behavioral and psychosocial interventions in diabetes: a conceptual

review.

Diabetes care 2007;30(10):2433-40.

?49.

Malinda Peeples; Donna Tomky; Kathy Mulcahy; Mark Peyrot; Linda Siminerio;

Evolution of the American Association of Diabetes Educators' diabetes education outcomes project.

The Diabetes educator 2007;33(5):794-817.

?50.

Mark Peyrot; Malinda Peeples; Donna Tomky; Denise

Charron-Prochownik; Todd Weaver;

Development of the American Association of Diabetes Educators'

Diabetes Self-management Assessment Report Tool.

The Diabetes educator 2007;33(5):818-26.

?51.

Denise Charron-Prochownik; Janice C Zgibor; Mark Peyrot; Malinda

Peeples; Janis McWilliams; Janice Koshinsky; William Noullet; Linda M Siminerio;

The Diabetes Self-management Assessment Report Tool (D-SMART): process evaluation and patient satisfaction.

The Diabetes educator 2007;33(5):833-8.

?52.

Janice C Zgibor; Mark Peyrot; Kristine Ruppert; William Noullet; Linda M Siminerio; Malinda Peeples; Janis McWilliams; Janice Koshinsky; Carla DeJesus; Sharlene Emerson; et al.

Using the American Association of Diabetes Educators Outcomes System to identify patient behavior change goals and diabetes educator

responses.

The Diabetes educator 2007;33(5):839-42.

?53.

Richard R Rubin; Mark Peyrot

Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy.

Current medical research and opinion 2007;23(8):1919-29.

?54.

Martha M Funnell; Tammy L Brown; Belinda P Childs; Linda B Haas;

Gwen M Hosey; Brian Jensen; Melinda Maryniuk; Mark Peyrot; John D Piette; Diane Reader; et al.

National standards for diabetes self-management education.

The Diabetes educator 2007;33(4):599-600, 602-4, 606 passim.

?55.

Martha M Funnell; Tammy L Brown; Belinda P Childs; Linda B Haas;

Gwen M Hosey; Brian Jensen; Melinda Maryniuk; Mark Peyrot; John D Piette; Diane Reader; et al.

National standards for diabetes self-management education.

Diabetes care 2007;30(6):1630-7.

?56.

Erin K Harvey; Chana E Fogel; Mark Peyrot; Kurt D Christensen; Sharon

F Terry; Joseph D McInerney

Providers' knowledge of genetics: A survey of 5915 individuals and

families with genetic conditions.

Genetics in medicine : official journal of the American College of Medical Genetics 2007;9(5):259-67.

?57.

Linda M Siminerio; Martha M Funnell; Mark Peyrot; Richard R Rubin

US nurses' perceptions of their role in diabetes care: results of the

cross-national Diabetes Attitudes Wishes and Needs (DAWN) study.

The Diabetes educator 2007;33(1):152-62.

?58.

Loretta Vileikyte; Jeffrey S Gonzalez; Howard Leventhal; Mark F Peyrot;

Richard R Rubin; Adam Garrow; Jan S Ulbrecht; Peter R Cavanagh;

Andrew J M Boulton

Patient Interpretation of Neuropathy (PIN) questionnaire: an instrument for assessment of cognitive and emotional factors associated with foot self-care.

Diabetes care 2006;29(12):2617-24.

?59.

Deborah Young-Hyman; Marian Tanofsky-Kraff; Susan Z Yanovski;

Margaret Keil; Marc L Cohen; Mark Peyrot; Jack A Yanovski

Psychological status and weight-related distress in overweight or

at-risk-for-overweight children.

Obesity (Silver Spring, Md.) 2006;14(12):2249-58.

?60.

Richard R Rubin; Mark Peyrot; Linda M Siminerio

Health care and patient-reported outcomes: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study.

Diabetes care 2006;29(6):1249-55.

?61.

Mark Peyrot; Richard R Rubin; Linda M Siminerio

Physician and nurse use of psychosocial strategies in diabetes care: results of the cross-national Diabetes Attitudes, Wishes and Needs

(DAWN) study.

Diabetes care 2006;29(6):1256-62.

?62.

M Peyrot; R R Rubin; T Lauritzen; S E Skovlund; F J Snoek; D R

Matthews; R Landgraf

Patient and provider perceptions of care for diabetes: results of the cross-national DAWN Study.

Diabetologia 2006;49(2):279-88.

?63.

Mark Peyrot; Richard R Rubin; Torsten Lauritzen; Soren E Skovlund;

Frank J Snoek; David R Matthews; Rüdiger Landgraf; Line Kleinebreil;

Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN)

study.

Diabetes care 2005;28(11):2673-9.

?64.

M Peyrot; R R Rubin; T Lauritzen; F J Snoek; D R Matthews; S E

Skovlund

Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs

(DAWN) Study.

Diabetic medicine : a journal of the British Diabetic

Association 2005;22(10):1379-85.

?65.

Loretta Vileikyte; Howard Leventhal; Jeffrey S Gonzalez; Mark Peyrot;

Richard R Rubin; Jan S Ulbrecht; Adam Garrow; Christine Waterman;

Peter R Cavanagh; Andrew J M Boulton

Diabetic peripheral neuropathy and depressive symptoms: the

association revisited.

Diabetes care 2005;28(10):2378-83.

?66.

Mark Peyrot; Richard R Rubin

Validity and reliability of an instrument for assessing health-related

quality of life and treatment preferences: the Insulin Delivery System Rating Questionnaire.

Diabetes care 2005;28(1):53-8.

?67.

Richard R Rubin; Mark Peyrot

Quality of life, treatment satisfaction, and treatment preference

associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies.

Diabetes care 2004;27(10):2495-7.

?68.

Zsolt Szabo; Taofeek Owonikoko; Mark Peyrot; Jozsef Varga; William B Mathews; Hayden T Ravert; Robert F Dannals; Gary Wand

Positron emission tomography imaging of the serotonin transporter in subjects with a history of alcoholism.

Biological psychiatry 2004;55(7):766-71.

?69.

Mark Peyrot

Depression: a quiet killer by any name.

Diabetes care 2003;26(10):2952-3.

?70.

Kathryn Mulcahy; Melinda Maryniuk; Malinda Peeples; Mark Peyrot;

Donna Tomky; Todd Weaver; Peggy Yarborough

Diabetes self-management education core outcomes measures.

The Diabetes educator 2003;29(5):768-70, 773-84, 787-8 passim.

Loretta Vileikyte; Mark Peyrot; Christine Bundy; Richard R Rubin;

Howard Leventhal; Pablo Mora; Jonathan E Shaw; Paul Baker; Andrew J M Boulton

The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument.

Diabetes care 2003;26(9):2549-55.

?72.

Tiffany L Gary; Jeanine M Genkinger; Eliseo Guallar; Mark Peyrot;

Frederick L Brancati

Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes.

The Diabetes educator 2003;29(3):488-501.

?73.

Sandra K Smith Speck; Mark Peyrot; Chiao-wen Hsiao

Insurance coverage and health care consumers' use of emergency

departments: has managed care made a difference?

Journal of hospital marketing & public relations 2003;15(1):3-18.

?74.

Richard R Rubin; Mark Peyrot

Was Willis right? Thoughts on the interaction of depression and

diabetes.

Diabetes/metabolism research and reviews 2002;18(3):173-5.

?75.

M F Peyrot

Theory in behavioral diabetes research.

Diabetes care 2001;24(10):1703-5.

L I Aljasem; M Peyrot; L Wissow; R R Rubin

The impact of barriers and self-efficacy on self-care behaviors in type 2 diabetes.

The Diabetes educator 2001;27(3):393-404.

?77.

R R Rubin; M Peyrot

Psychological issues and treatments for people with diabetes.

Journal of clinical psychology 2001;57(4):457-78.

?78.

D G Marrero; M Peyrot; S Garfield

Promoting behavioral science research in diabetes.

Diabetes care 2001;24(1):1-2.

?79.

P E Murphy; J W Ciarrocchi; R L Piedmont; S Cheston; M Peyrot; G

Fitchett

The relation of religious belief and practices, depression, and

hopelessness in persons with clinical depression.

Journal of consulting and clinical psychology 2000;68(6):1102-6.

?80.

D L Mangold; M Peyrot; P Giggey; G S Wand

Endogenous opioid activity is associated with obsessive-compulsive

symptomology in individuals with a family history of alcoholism.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000;22(6):595-607.

?81.

M Peyrot

Behavior change in diabetes education.

The Diabetes educator 1999;25(6 Suppl):62-73.

?82.

M Peyrot; J F McMurry; D F Kruger

A biopsychosocial model of glycemic control in diabetes: stress, coping

and regimen adherence.

Journal of health and social behavior 1999;40(2):141-58.

?83.

R R Rubin; M Peyrot

Quality of life and diabetes.

Diabetes/metabolism research and reviews 1999;15(3):205-18.

?84.

M Peyrot; R R Rubin

Persistence of depressive symptoms in diabetic adults.

Diabetes care 1999;22(3):448-52.

?85.

M Peyrot; N M Alperstein; D Van Doren; L G Poli

Direct-to-consumer ads can influence behavior. Advertising increases consumer knowledge and prescription drug requests.

Marketing health services 1998;18(2):26-32.

?86.

M Peyrot; R R Rubin

Levels and risks of depression and anxiety symptomatology among diabetic adults.

Diabetes care 1997;20(4):585-90.

?87.

M Peyrot

Causal analysis: theory and application.

Journal of pediatric psychology 1996;21(1):3-24.

?88.

C T Prino; M Peyrot

The effect of child physical abuse and neglect on aggressive, withdrawn, and prosocial behavior.

Child abuse & neglect 1994;18(10):871-84.

?89.

M Peyrot; R R Rubin

Structure and correlates of diabetes-specific locus of control.

Diabetes care 1994;17(9):994-1001.

?90.

M Peyrot; R R Rubin

Modeling the effect of diabetes education on glycemic control.

The Diabetes educator 1994;20(2):143-8.

?91.

R R Rubin; M Peyrot

Implications of the DCCT. Looking beyond tight control.

Diabetes care 1994;17(3):235-6.

?92.

M Peyrot; S Yen; C A Baldassano